Content
November 2014, Volume 15, Issue 8
- 801-812 The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening
by Pauline Chauvin & Jean-Michel Josselin & Denis Heresbach - 813-828 How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011
by Astrid Kiil & Kurt Houlberg - 829-840 Methodological reviews of economic evaluations in health care: what do they target?
by Maria-Florencia Hutter & Roberto Rodríguez-Ibeas & Fernando Antonanzas - 841-851 On social polarization and ordinal variables: the case of self-assessed health
by Alessio Fusco & Jacques Silber - 853-867 The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study
by Petra Baji & Milena Pavlova & László Gulácsi & Miklós Farkas & Wim Groot - 869-883 Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model
by G. Ramos & Antoinette Asselt & Sandra Kuiper & Johan Severens & Tanja Maas & Edward Dompeling & J. Knottnerus & Onno Schayck - 885-896 Population ageing and healthcare expenditure projections: new evidence from a time to death approach
by Claudia Geue & Andrew Briggs & James Lewsey & Paula Lorgelly - 897-897 Erratum to: Cost-effectiveness of febuxostat in chronic gout
by Stephen Beard & Birgitta Scheele & George Nuki & Isobel Pearson
September 2014, Volume 15, Issue 7
- 675-680 HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain
by L. Gulácsi & M. Péntek - 681-695 Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making
by Karin Cerri & Martin Knapp & Jose-Luis Fernandez - 697-708 Lead me not into temptation: drug price regulation and dispensing physicians in Switzerland
by Maurus Rischatsch - 709-716 A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions
by Douwe Postmus & Tommi Tervonen & Gert Valkenhoef & Hans Hillege & Erik Buskens - 717-735 Persistence of physical activity in middle age: a nonlinear dynamic panel approach
by Narimasa Kumagai & Seiritsu Ogura - 737-746 Choice of insurer for basic health insurance restricted by supplementary insurance
by Daniëlle Duijmelinck & Wynand Ven - 747-757 Employment effects of hospital privatization in Germany
by Mareike Heimeshoff & Jonas Schreyögg & Oliver Tiemann - 759-766 Health tourism on the rise? Evidence from the Balance of Payments Statistics
by Chung-Ping Loh - 767-772 Cost-effectiveness of lung transplantation and its evolution: the Portuguese case
by Luis Mendonça & Julian Perelman & Vanessa Rodrigues & José Fragata - 773-785 Applying discrete choice modelling in a priority setting: an investigation of public preferences for primary care models
by Chiara Seghieri & Alessandro Mengoni & Sabina Nuti
July 2014, Volume 15, Issue 6
- 563-566 Health-related development aid: what comes after it?
by Steffen Fleßa - 567-576 The effect of job loss on body weight during an economic collapse
by Sif Jónsdóttir & Tinna Ásgeirsdóttir - 577-589 Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
by Jörg Ruof & Friedrich Schwartz & J.-Matthias Schulenburg & Charalabos-Markos Dintsios - 591-598 Does health promote economic growth? Portuguese case study: from dictatorship to full democracy
by Sónia Morgado - 599-610 Association between fee-for-service expenditures and morbidity burden in primary care
by Troels Kristensen & Kim Olsen & Henrik Schroll & Janus Thomsen & Anders Halling - 611-621 Preference for practice: a Danish study on young doctors’ choice of general practice using a discrete choice experiment
by Line Pedersen & Dorte Gyrd-Hansen - 623-643 An empirical analysis of the multimarket contact theory in pharmaceutical markets
by Javier Coronado & Sergi Jiménez-Martín & Pedro Marín - 645-652 Can health public expenditure reduce the tragic consequences of road traffic accidents? The EU-27 experience
by José Castillo-Manzano & Mercedes Castro-Nuño & Xavier Fageda - 653-660 Costs of diabetes and its complications in Poland
by Joanna Leśniowska & Agata Schubert & Michał Wojna & Iwona Skrzekowska-Baran & Marta Fedyna - 661-673 Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France
by Hassan Serrier & Hélène Sultan-Taieb & Danièle Luce & Sophie Bejean
June 2014, Volume 15, Issue 5
- 449-452 Health technology assessments in England: an analysis of the NICE Medical Technologies Evaluation Programme
by William Green & John Hutton - 453-463 Cost-effectiveness of febuxostat in chronic gout
by Stephen Beard & Birgitta Scheele & George Nuki & Isobel Pearson - 465-475 Predicting productivity based on EQ-5D: an explorative study
by Marieke Krol & Elly Stolk & Werner Brouwer - 477-487 The effects of rebate contracts on the health care system
by Julia Graf - 489-496 Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores
by Fang-Ju Lin & Jennifer Samp & Alexis Munoz & Pei Wong & A. Pickard - 497-514 Explaining variations in breast cancer screening across European countries
by Ansgar Wübker - 515-531 Identifying covariates of population health using extreme bound analysis
by Fabrizio Carmignani & Sriram Shankar & Eng Tan & Kam Tang - 533-551 Testing the red herring hypothesis on an aggregated level: ageing, time-to-death and care costs for older people in Sweden
by Martin Karlsson & Florian Klohn - 553-561 Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach
by Arieh Gavious & Dan Greenberg & Ariel Hammerman & Ella Segev
May 2014, Volume 15, Issue 4
- 335-340 Orphan drugs policies: a suitable case for treatment
by Michael Drummond & Adrian Towse - 341-351 Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care: population-based Cohort study and Markov model
by Martin Gulliford & Judith Charlton & Nawaraj Bhattarai & Christopher Charlton & Caroline Rudisill - 353-362 Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
by Carole Dembek & Leigh White & Jayson Quach & Andrea Szkurhan & Nazia Rashid & M. Blasco - 363-372 Optimal choice on prevention and cure: a new economic analysis
by Mario Menegatti - 373-388 Announcement effects of health policy reforms: evidence from the abolition of Austria’s baby bonus
by Beatrice Brunner & Andreas Kuhn - 389-399 Valuing health at the end of life: an empirical study of public preferences
by Koonal Shah & Aki Tsuchiya & Allan Wailoo - 401-410 Explaining differences in remuneration rates of nursing homes in Germany
by Roman Mennicken & Boris Augurzky & Heinz Rothgang & Jürgen Wasem - 411-431 Effects of health care decentralization in Spain from a citizens’ perspective
by José-Ignacio Antón & Rafael Muñoz de Bustillo & Enrique Fernández Macías & Jesús Rivera - 433-437 Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries
by Manuel Hens & Ana Villaverde-Hueso & Veronica Alonso & Ignacio Abaitua & Manuel Posada de la Paz - 439-445 Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD
by Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten - 447-447 Erratum to: Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD
by Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten
April 2014, Volume 15, Issue 3
- 223-228 Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
by María-Isabel Farfan-Portet & Sophie Gerkens & Isabelle Lepage-Nefkens & Irmgard Vinck & Frank Hulstaert - 229-242 Low birth weight and health expenditures from birth to late adolescence
by Michael Hummer & Thomas Lehner & Gerald Pruckner - 243-252 Economic evaluation of nurse-led intensive care follow-up programmes compared with standard care: the PRaCTICaL trial
by R. Hernández & D. Jenkinson & L. Vale & B. Cuthbertson - 253-263 Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity
by Bruce Wang & Edwin Wong & Rafael Alfonso-Cristancho & Hao He & David Flum & David Arterburn & Louis Garrison & Sean Sullivan - 265-279 Education, cognition, health knowledge, and health behavior
by Naci Mocan & Duha Altindag - 281-288 Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling?
by Feng Xie & Eleanor Pullenayegum & Kathryn Gaebel & Mark Oppe & Paul Krabbe - 289-302 The effect of quality and socio-demographic variables on efficiency measures in primary health care
by José Cordero Ferrera & Eva Cebada & Luis Murillo Zamorano - 303-311 Health, social and economic consequences of hypersomnia: a controlled national study from a national registry evaluating the societal effect on patients and their partners
by Poul Jennum & Rikke Ibsen & Kirsten Avlund & Jakob Kjellberg - 313-321 Blood donation as a public good: an empirical investigation of the free rider problem
by Ignacio Abásolo & Aki Tsuchiya - 323-334 Equity in specialist waiting times by socioeconomic groups: evidence from Spain
by Ignacio Abásolo & Miguel Negrín-Hernández & Jaime Pinilla
March 2014, Volume 15, Issue 2
- 113-116 Is the US “leading from behind” on health policy?
by Peter Neumann & Cayla Saret - 117-132 Is there room for containing healthcare costs? An analysis of regional spending differentials in Italy
by Maura Francese & Marzia Romanelli - 133-142 Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
by Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt - 143-156 Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism
by Moshe Levy & Adi Rizansky - 157-174 Economic evaluations of homeopathy: a review
by Petter Viksveen & Zofia Dymitr & Steven Simoens - 175-186 Hospital efficiency under prospective reimbursement schemes: an empirical assessment for the case of Germany
by Helmut Herwartz & Christoph Strumann - 187-201 The impact of health worker migration on development dynamics: evidence of wealth effects from Africa
by Simplice Asongu - 203-221 Socioeconomic inequalities in adult obesity risk in Canada: trends and decomposition analyses
by Mohammad Hajizadeh & M. Karen Campbell & Sisira Sarma
January 2014, Volume 15, Issue 1
- 1-5 The organ crisis: a disaster of our own making
by T. Randolph Beard & Rigmar Osterkamp - 7-18 Health state utilities for skeletal-related events secondary to bone metastases
by Louis Matza & Karen Chung & Kate Brunt & John Brazier & Ada Braun & Brooke Currie & Andrew Palsgrove & Evan Davies & Jean-Jacques Body - 19-39 The impact of tobacco prices on smoking onset in Vietnam: duration analyses of retrospective data
by G. Guindon - 41-55 Willingness-to-accept reductions in HIV risks: conditional economic incentives in Mexico
by Omar Galárraga & Sandra Sosa-Rubí & César Infante & Paul Gertler & Stefano Bertozzi - 57-68 The effect of health on labour supply in nine former Soviet Union countries
by Yevgeniy Goryakin & Lorenzo Rocco & Marc Suhrcke & Bayard Roberts & Martin McKee - 69-82 Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
by Yevgeniy Samyshkin & Robert Kotchie & Ann-Christin Mörk & Andrew Briggs & Eric Bateman - 83-91 Changes in the remuneration system for general practitioners: effects on contact type and consultation length
by Christel Dijk & Robert Verheij & Hans te Brake & Peter Spreeuwenberg & Peter Groenewegen & Dinny Bakker - 93-112 Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique
by Bonny Parkinson & Sallie-Anne Pearson & Rosalie Viney
May 2014, Volume 15, Issue 1
- 1-4 Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries
by László Gulácsi - 5-11 Statistical and regulatory considerations in assessments of interchangeability of biological drug products
by Lászlo Tóthfalusi & László Endrényi & Shein-Chung Chow - 13-25 Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
by László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga - 27-34 Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries
by László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji - 35-43 Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries
by Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi - 45-52 Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
by Petra Baji & Márta Péntek & Sándor Szántó & Pál Géher & László Gulácsi & Orsolya Balogh & Valentin Brodszky - 53-64 Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
by Petra Baji & Márta Péntek & László Czirják & Zoltán Szekanecz & György Nagy & László Gulácsi & Valentin Brodszky - 65-71 Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
by Valentin Brodszky & Petra Baji & Orsolya Balogh & Márta Péntek - 73-82 Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective
by Márta Péntek & Bernadette Rojkovich & László Czirják & Pál Géher & Péter Keszthelyi & Attila Kovács & László Kovács & Zita Szabó & Zoltán Szekanecz & László Tamási & Ágnes Tóth & Ilona Ujfalussy & Noémi Hevér & Bálint Strbák & Petra Baji & Valentin Brodszky & László Gulácsi - 83-92 Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists
by Márta Péntek & László Gulácsi & Bernadette Rojkovich & Valentin Brodszky & Job Exel & Werner Brouwer - 93-100 Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis
by Katalin Gulyas & Nora Bodnar & Zsofia Nagy & Szilvia Szamosi & Agnes Horvath & Andrea Vancsa & Edit Vegh & Zoltan Szabo & Gabriella Szucs & Zoltan Szekanecz & Sandor Szanto - 101-109 Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres
by Orsolya Balogh & Valentin Brodszky & László Gulácsi & Emese Herédi & Krisztina Herszényi & Hajnalka Jókai & Sarolta Kárpáti & Petra Baji & Éva Remenyik & Andrea Szegedi & Péter Holló - 111-119 Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
by Emese Herédi & Fanni Rencz & Orsolya Balogh & László Gulácsi & Krisztina Herszényi & Péter Holló & Hajnalka Jókai & Sarolta Kárpáti & Márta Péntek & Éva Remenyik & Andrea Szegedi & Valentin Brodszky - 121-128 Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
by Mandel Michael & Anita Bálint & Barbara Lovász & László Gulácsi & Bálint Strbák & Petra Golovics & Klaudia Farkas & Zsuzsanna Kürti & Blanka Szilágyi & Anna Mohás & Tamás Molnár & Péter Lakatos - 129-129 Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
by Michael Mandel & Anita Bálint & Barbara Lovász & László Gulácsi & Bálint Strbák & Petra Golovics & Klaudia Farkas & Zsuzsanna Kürti & Blanka Szilágyi & Anna Mohás & Tamás Molnár & Péter Lakatos - 131-135 Economic burden of long-term care of rheumatoid arthritis patients in Hungary
by Zoltán Horváth & Andor Sebestyén & August Österle & Dóra Endrei & József Betlehem & András Oláh & László Imre & Gabriella Bagosi & Imre Boncz - 137-141 Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010
by Imre Boncz & Réka Vajda & István Ágoston & Dóra Endrei & Andor Sebestyén
December 2013, Volume 14, Issue 6
- 847-852 Channeling health economics research initiatives to improve decision-making processes in the EU
by F. Antonanzas & R. Rodríguez-Ibeas - 853-861 Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease
by Monia Marchetti & Nicola Liberato & Antonio Sabatino & Gino Corazza - 863-873 The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
by Ingrid Lekander & Fredrik Borgström & Jörgen Lysholm & Ronald Vollenhoven & Staffan Lindblad & Pierre Geborek & Gisela Kobelt - 875-885 Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
by P. Laires & F. Exposto & R. Mesquita & A. Martins & L. Cunha-Miranda & J. Fonseca - 887-899 The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies
by Jen Kruger & Alan Brennan - 901-909 Internal validation of models with several interventions
by Afschin Gandjour & Amiram Gafni - 911-918 Quantifying short run cost-effectiveness during a gradual implementation process
by Gijs Wetering & Willem Woertman & Andre Verbeek & Mireille Broeders & Eddy Adang - 919-927 Explaining length of stay variation of episodes of care in the Netherlands
by Siok Tan & Leona Hakkaart-van Roijen & B. Ineveld & W. Redekop - 929-938 Managing for efficiency in health care: the case of Greek public hospitals
by Panagiotis Mitropoulos & Ioannis Mitropoulos & Aris Sissouras - 939-945 Treatment costs of attention deficit hyperactivity disorder in Germany
by Sebastian Braun & Jan Zeidler & Roland Linder & Susanne Engel & Frank Verheyen & Wolfgang Greiner - 947-957 Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information
by Leyla Mohseninejad & Talitha Feenstra & Henriëtte Horst & Hèlen Woutersen-Koch & Erik Buskens - 959-969 The impact of generic reference pricing in Italy, a decade on
by Simone Ghislandi & Patrizio Armeni & Claudio Jommi - 971-977 Maximal endurable time states and the standard gamble: more preference reversals
by P. Stalmeier & A. Verheijen - 979-994 How efficient are Greek hospitals? A case study using a double bootstrap DEA approach
by Kostas Kounetas & Fotis Papathanassopoulos - 995-1002 Cost-effectiveness analysis, prevention of atopic dermatitis by oral application of bacterial lysate in newborns/small children
by Peter Kiencke & Kristina Viehmann & Reinhard Rychlik - 1003-1013 Long-term health investment when people underestimate their adaptation to old age-related health problems
by Octave Jokung & Serge Macé - 1015-1026 Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
by Bernhard Ultsch & Ingrid Köster & Thomas Reinhold & Anette Siedler & Gérard Krause & Andrea Icks & Ingrid Schubert & Ole Wichmann - 1027-1034 TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial
by G. Koning & E. Adang & P. Stalmeier & F. Keus & P. Vriens & C. Laarhoven - 1035-1048 Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation
by Björn Stollenwerk & Afschin Gandjour & Markus Lüngen & Uwe Siebert
October 2013, Volume 14, Issue 5
- 709-713 Could co-payments on drugs help to make EU health care systems less open to political influence?
by Livio Garattini & Katelijne Vooren - 715-723 Analysis of HIV/AIDS DRG in Portugal: a hierarchical finite mixture model
by Sara Dias & Valeska Andreozzi & Rosário Martins - 725-737 Soft budget constraints in health care: evidence from Italy
by Rosella Levaggi & Francesco Menoncin - 739-748 Public preferences for establishing nephrology facilities in Greenland: estimating willingness-to-pay using a discrete choice experiment
by Trine Kjær & Mickael Bech & Christian Kronborg & Morten Mørkbak - 749-759 Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia
by Keith Tolley & Catherine Goad & Yunni Yi & Penny Maroudas & Amin Haiderali & Gwilym Thompson - 761-773 Examining the determinants of drug launch delay in pre-TRIPS India
by Saradindu Bhaduri & Thomas Brenner - 775-787 Evaluating the redistributive impact of public health expenditure using an insurance value approach
by Amedeo Spadaro & Lucia Mangiavacchi & Ignacio Moral-Arce & Marta Adiego-Estella & Angela Blanco-Moreno - 789-797 The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop
by Carla Guerriero & John Cairns & Ian Roberts & Anthony Rodgers & Robyn Whittaker & Caroline Free - 799-808 Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study
by Sarah Mostardt & Nikola Hanhoff & Jürgen Wasem & Armin Goetzenich & Knud Schewe & Eva Wolf & Christoph Mayr & Hans Jaeger & Holger Pfaff & Stephan Dupke & Anja Neumann - 809-820 Hospital readmission among elderly patients
by Afsaneh Bjorvatn - 821-834 What determines health: a causal analysis using county level data
by Andrew Rettenmaier & Zijun Wang - 835-846 Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries
by Christian Eckmann & Matthew Wasserman & Faisal Latif & Graeme Roberts & Axelle Beriot-Mathiot
August 2013, Volume 14, Issue 4
- 569-571 The present state of health economics: a critique and an agenda for the future
by Peter Zweifel - 573-586 Welfare standards in hospital mergers
by Katalin Katona & Marcel Canoy - 587-599 Assessing the impact of national antibiotic campaigns in Europe
by M. Filippini & L. Ortiz & G. Masiero - 601-613 What do physicians dislike about managed care? Evidence from a choice experiment
by Maurus Rischatsch & Peter Zweifel - 615-627 What accounts for the regional differences in the utilisation of hospitals in Germany?
by Boris Augurzky & Thomas Kopetsch & Hendrik Schmitz - 629-638 Palliative treatment of colorectal cancer in Germany: cost of care and quality of life
by Martin Emmert & Katharina Pohl-Dernick & Axel Wein & Frank Dörje & Susanne Merkel & Frank Boxberger & Gudrun Männlein & Robert Joost & Hans-Detlev Harich & Roland Thiemann & Christof Lamberti & Markus Neurath & Werner Hohenberger & Oliver Schöffski - 639-653 Measuring Worksite Health Promotion Programs: an application of Structural Equation Modeling with ordinal data
by Fredrik Ødegaard & Pontus Roos - 655-665 The economic burden of atherothrombosis in Greece: results from the THESIS study
by Nikos Maniadakis & Georgia Kourlaba & Dennis Cokkinos & Aggeliki Angeli & John Kyriopoulos - 667-675 Competition in prescription drug markets: the roles of trademarks, advertising, and generic names
by Roger Feldman & Félix Lobo - 677-695 The effect of stimulants and their combined use with cigarettes on mortality: the case of betel quid
by Shao-Hsun Keng & Sheng-Jang Sheu - 697-702 The effect of chronic conditions on stated preferences for health
by A. Pickard & Rima Tawk & James Shaw - 703-705 Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776
by Christopher Sampson & David Whitehurst & Andrew Street - 707-708 Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A reply to Christopher James Sampson
by Peter Kooreman & Erik Baars
June 2013, Volume 14, Issue 3
- 363-366 HAS to be NICE?
by Gérard Pouvourville - 367-372 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
by Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder - 373-381 Redistributional consequences of early childhood intervention
by Tim Lohse & Peter Lutz & Christian Thomann - 383-390 Problems of priority change in kidney allocation and beyond
by Marlies Ahlert & Hartmut Kliemt - 391-406 Bargaining and the provision of health services
by Luigi Siciliani & Anderson Stanciole - 407-413 Terminal patients in Belgian nursing homes: a cost analysis
by Steven Simoens & Betty Kutten & Emmanuel Keirse & Paul Berghe & Claire Beguin & Marianne Desmedt & Myriam Deveugele & Christian Léonard & Dominique Paulus & Johan Menten - 415-429 Effects of competition on hospital quality: an examination using hospital administrative data
by Alfons Palangkaraya & Jongsay Yong - 431-442 Welfare-related health inequality: does the choice of measure matter?
by Joachim Frick & Nicolas Ziebarth - 443-455 Diffusion of innovations in social interaction systems. An agent-based model for the introduction of new drugs in markets
by Julio Pombo-Romero & Luis Varela & Carlos Ricoy - 457-469 Does the US health care safety net discourage private insurance coverage?
by Xuezheng Qin & Gordon Liu - 471-479 The impact of time cost of physical exercise on health outcomes by older adults: the DR’s EXTRA Study
by Virpi Kuvaja-Köllner & Hannu Valtonen & Pirjo Komulainen & Maija Hassinen & Rainer Rauramaa - 481-493 Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation—results for Canada, Italy, Sweden and Switzerland
by Jonas Nilsson & Örjan Åkerborg & Gaëlle Bégo-Le Bagousse & Mårten Rosenquist & Peter Lindgren - 495-502 Drug expenditure of high-cost patients and their characteristics in Finland
by Leena Saastamoinen & Jouko Verho - 503-506 Systems GMM estimates of the health care spending and GDP relationship: a note
by Saten Kumar - 507-514 Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
by Ruth Brown & Sean Stern & Sujith Dhanasiri & Steve Schey - 515-526 Inter-regional competition and quality in hospital care
by Hiroshi Aiura - 527-538 Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries
by Richard Heijink & Xander Koolman & Gert Westert - 539-550 Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients
by Lene Lunde - 551-568 How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus
by Thomas Wilke & Antje Groth & Sabrina Mueller & Dallas Reese & Roland Linder & Susanne Ahrens & Frank Verheyen
April 2013, Volume 14, Issue 2
- 153-159 Resource allocation strategies in Southeastern European health policy
by Mihajlo Jakovljevic - 161-170 Self-control and support for anti-smoking policies among smokers, ex smokers, and never smokers
by Lourdes Badillo Amador & Ángel López Nicolás - 171-183 The welfare implications of disability for older people in Ireland
by John Cullinan & Brenda Gannon & Eamon O’Shea - 185-195 Economic evaluation of URMEL-ICE, a school-based overweight prevention programme comprising metabolism, exercise and lifestyle intervention in children
by Dorothea Kesztyüs & Anja Schreiber & Tamara Wirt & Martina Wiedom & Jens Dreyhaupt & Susanne Brandstetter & Benjamin Koch & Olivia Wartha & Rainer Muche & Martin Wabitsch & Reinhold Kilian & Jürgen Steinacker - 197-209 The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries
by Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast - 211-219 Trends in social class inequalities in the use of health care services within the Spanish National Health System, 1993–2006
by Laia Palència & Albert Espelt & Maica Rodríguez-Sanz & Katia B. Rocha & M. Isabel Pasarín & Carme Borrell - 221-230 An analysis of the influence of framework aspects on the study design of health economic modeling evaluations
by Sebastian Gurtner - 231-241 Mapping utility scores from the Barthel index
by Billingsley Kaambwa & Lucinda Billingham & Stirling Bryan - 243-252 The influence of social deprivation on length of hospitalisation
by Engin Yilmaz & Denis Raynaud - 253-265 Determinants of healthcare system’s efficiency in OECD countries
by Sharon Hadad & Yossi Hadad & Tzahit Simon-Tuval - 267-276 Organisational determinants of production and efficiency in general practice: a population-based study
by Kim Olsen & Dorte Gyrd-Hansen & Torben Sørensen & Troels Kristensen & Peter Vedsted & Andrew Street - 277-285 Using respondents’ uncertainty scores to mitigate hypothetical bias in community-based health insurance studies
by Hermann Donfouet & Pierre-Alexandre Mahieu & Eric Malin - 287-295 Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan
by Chee-Ruey Hsieh & Ya-Ming Liu & Chia-Lin Chang - 297-306 Moving beyond a limited follow-up in cost-effectiveness analyses of behavioral interventions
by Rilana Prenger & Marcel Pieterse & Louise Braakman-Jansen & Job Palen & Lieke Christenhusz & Erwin Seydel - 307-314 Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients
by Nick Kontodimopoulos & Panagiotis Bozios & John Yfantopoulos & Dimitris Niakas - 315-321 Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom
by Trudy Owens & Nikos Evangelou & David Whynes - 323-344 The impact of health insurance mandates on drug innovation: evidence from the United States
by Natalie Chun & Minjung Park - 345-355 Impact of parallel trade on pharmaceutical firm’s profits: rise or fall?
by Shen Guo & Bin Hu & Hai Zhong - 357-360 The Grossman model after 40 years: a reply to Peter Zweifel
by Robert Kaestner - 361-362 The Grossman model after 40 years: response to Robert Kaestner
by Peter Zweifel
July 2013, Volume 14, Issue 1
- 1-3 The development of new research methods for the valuation of EQ-5D-5L
by Nancy Devlin & Paul Krabbe - 5-13 Introducing the composite time trade-off: a test of feasibility and face validity
by Bas Janssen & Mark Oppe & Matthijs Versteegh & Elly Stolk - 15-24 The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework
by Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin - 25-31 Lead versus lag-time trade-off variants: does it make any difference?
by Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin - 33-42 Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states
by Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés - 43-51 Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
by Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk - 53-64 Time trade-off: one methodology, different methods
by Arthur Attema & Yvette Edelaar-Peeters & Matthijs Versteegh & Elly Stolk - 65-73 One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands
by Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin
February 2013, Volume 14, Issue 1
- 1-4 Paying doctors for performance
by Gérard Pouvourville - 5-10 Is health care a luxury or a necessity or both? Evidence from Turkey
by Nilgun Yavuz & Veli Yilanci & Zehra Ozturk - 11-19 Measuring health outcomes of adolescents: report from a pilot study
by Yemi Oluboyede & Sandy Tubeuf & Chris McCabe - 21-39 Federal state differentials in the efficiency of health production in Germany: an artifact of spatial dependence?
by Stefan Felder & Harald Tauchmann - 41-56 The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007
by Frank Lichtenberg - 57-66 Valuing EQ-5D using Time Trade-Off in France
by Julie Chevalier & Gérard Pouvourville - 67-73 What can we learn from international comparisons of costs by DRG?
by M. Pirson & L. Schenker & D. Martins & Duong Dung & J. Chalé & P. Leclercq - 75-84 Determinants of household direct and indirect costs: an insight for health-seeking behaviour in Burkina Faso
by Tin Su & Steffen Flessa - 85-94 A cost-effectiveness analysis of the Incredible Years parenting programme in reducing childhood health inequalities
by Donal O’Neill & Sinéad McGilloway & Michael Donnelly & Tracey Bywater & Paul Kelly - 95-105 Body weight and health-related quality of life in Catalonia, Spain
by Juan Oliva-Moreno & Ana Gil-Lacruz - 107-115 Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall
by E. Wetering & E. Stolk & N. Exel & W. Brouwer - 117-131 Key issues in the design of pay for performance programs
by Frank Eijkenaar - 133-151 Food prices and overweight patterns in Italy
by L. Pieroni & D. Lanari & L. Salmasi
December 2012, Volume 13, Issue 6
- 677-682 The Grossman model after 40 years
by Peter Zweifel - 683-705 Informal caring-time and caregiver satisfaction
by Miriam Marcén & José Molina - 707-722 Measuring attitude toward social health insurance
by Chung-Ping Loh & Katrin Nihalani & Oliver Schnusenberg